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CHAPTER 1: INTRODUCTION 
1.1 Photodynamic therapy (PDT) 
Photodynamic therapy is a cancer treatment modality. It is primarily used in treating pre-
malignant and early stage cancers [1]. PDT involves three major components: a photosensitizer, 
light source, and tissue oxygen. Photosensitizers are sensitizing agents which are activated 
upon exposure to light of particular wavelength corresponding to their absorption spectrum. 
Photofrin, Foscan and Aminolevulinic acid are some of the currently available photosensitizers 
[2]. Lasers (argon dye, diode) and light-emitting diodes are used as light sources for PDT [3, 4].  
Mechanism of PDT 
Upon absorption of light, photosensitizer reaches its excited state. Two types of 
reactions can occur at this point. The excited photosensitizer can directly react with substrates 
like cell membrane to form radicals. Radicals then interact with oxygen to produce oxygenated 
products. This is known as a type I reaction. Alternatively, energy from the excited 
photosensitizer is directly transferred to oxygen thus forming singlet oxygen. This is known as a 
type II reaction [5]. Extent of the photodamage and cytotoxicity depends upon many factors 
such as the type and localization of photosensitizer, total dose of PDT, oxygen availability and 
time between administration of the photosensitizer and light exposure. PDT causes tumor 
destruction through direct tumor cell killing, vascular damage and activation of immune 
response [6]. 
PDT and apoptosis: 
Apoptosis is shown with PDT in various cell lines [7-9]. Our previous studies have shown 
effect of modulation of de novo sphingolipid biosynthesis and ceramide synthases in PDT-
induced apoptosis [10-12]. Studies have shown that PDT damages anti-apoptotic protein Bcl2 
[13-15]. PDT was shown to induce Bax associated with mitochondria and cytochrome c release 
[9, 16-19].  
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1.2 C6-pyridinium ceramide (LCL29): 
 
Figure 1.1 LCL29 structure (Courtesy of Avanti Polar Lipids) 
LCL29 is a cationic water soluble C6-ceramide analog. Fixed positive charge allows 
targeting and delivery of LCL29 in to negatively charged mitochondria [20, 21]. LCL29 promotes 
Bax translocation to mitochondria leading to induction of mitochondrial membrane 
permeabilization and subsequent release of cytochrome c in to cytosol [22]. LCL29 in 
combination with PDT led to enhanced tumor cures [23, 24].  
1.3 FENRETINIDE (4HPR): 
4HPR is a synthetic retinoic acid derivative used for the treatment of cancer. 4HPR has 
been shown to be effective for treatment of breast cancer [25] and oral leukoplakia [26]. 
 
Figure 1.2 Structure of 4HPR  (Courtesy of MedChem Express) 
4HPR induces apoptosis in human head and neck squamous cell carcinoma (HNSCC), 
ovarian carcinoma and neuroblastoma cell lines [27-30]. Mechanism of apoptosis induction by 
4HPR is not fully understood. Induction of Bax associated with mitochondria and cytochrome c 
release has been shown after 4HPR [9, 16-19].  
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1.4 Apoptosis 
Apoptosis is a form of programmed cell death. Apoptosis is distinguished in to intrinsic 
and extrinsic apoptosis. Mitochondrial accumulation of Bax and cytochrome c (cyt c) 
release/redistribution are characteristics of mitochondrial or intrinsic apoptotic pathway [31]. Bax 
is a pro-apoptotic protein residing in cytosol, but translocates to mitochondria upon stress. 
Cytochrome c released in to the cytosol forms apoptosome by combining with Apaf-1 and 
procaspase-9 to activate caspase-9 which in turn activates caspase-3. Downstream targets are 
cleaved by active caspase-3 leading to apoptosis. Bcl2, an anti-apoptotic protein, has been 
shown to inhibit apoptosis by inhibiting Bax [32]. Pharmacological inhibitors can be used to test 
the role of apoptosis in stress-induced cell death. zVAD-fmk (zVAD) is a cell-permeable 
pancaspase inhibitor which irreversibly binds to caspase proteases at the catalytic site and 
inhibits induction of apoptosis [33]. ABT-199 (ABT) is a selective inhibitor of Bcl2 [34]. 
1.5 De novo sphingolipid biosynthesis  
Ceramide can be generated in endoplasmic reticulum (ER) through the de novo 
sphingolipid (SL) biosynthesis pathway [35]. The de novo SL pathway involves ceramide 
synthase (CERS)-mediated conversion of dihydrosphingosine in to dihydroceramide by addition 
of a fatty acyl group. In the next step, dihydroceramide is further converted to ceramide by 
dihydroceramide desaturase-dependent reaction. Fumonisin B1 (FB) is an inhibitor of ceramide 
synthase [36, 37]. Fenretinide causes inhibition of dihydroceramide desaturase. 
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Figure 1.3 De novo sphingolipid biosynthesis pathway 
 
1.6. Hypothesis 
 The hypothesis is that cell killing after PDT, PDT+4HPR and PDT+LCL29 is mediated 
via the de novo sphingolipid biosynthesis and mitochondrial apoptosis  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials 
Pc4 [HOSiPcOSi(CH3)2(CH2)3N(CH3)2], a silicon phthalocyanine photosensitizer was 
graciously provided by Dr. Malcolm E. Kenney (Case Western Reserve University, Cleveland, 
OH, USA). LCL29 [d-erythro-2-N-(6’-1”-pyridinium-hexanoyl sphingosine bromide)] was 
purchased from Avanti Polar Lipids (Alabaster, AL, USA). 4HPR [N-(4-Hydroxyphenyl) 
retinamide] was obtained from Sigma-Aldrich (St. Louis, MO, USA). Inhibitors were obtained 
from the following suppliers: Fumonisin B1 (Cayman Chemicals, Ann Arbor, MI, USA), zVAD-
fmk (MBL International Corporation, Woburn, MA, USA) and ABT-199 (Selleck Chemicals, 
Houston, Texas, USA). DMEM/F-12 medium was purchased from Thermo-Fisher Scientific 
(Waltham, MA, USA). Fetal bovine serum (FBS) and goat serum were obtained from Sigma-
Aldrich. Phosphate-buffered saline (PBS) without calcium and magnesium used for confocal 
microscopy was purchased from Life Technologies (Carlsbad, CA, USA). Phosphate-buffered 
saline with calcium and magnesium used for mass spectrometry and DEVDase assay was also 
purchased from Life Technologies. 
2.2 Cell culture 
SCC17B, a human head and neck squamous cell carcinoma cell line derived from larynx 
was supplied by Dr. Thomas Carey (University of Michigan, Ann Arbor, MI, USA). Cells were 
grown in DMEM/F-12 medium containing 10% fetal bovine serum, 100 units/ml penicillin, and 
100 µg/ml streptomycin (Life Technologies) in a humidified incubator at 37°C and 5% CO2.  For 
all experiments, unless indicated otherwise, incubation of cells was carried out in a humidified 
incubator at 37°C and 5% CO2.  All treatments, as well as staining with Mitotracker Red 
CMXRos (see below) were added to cells in growth medium.  
 
 
6 
 
2.3 Treatments  
After overnight (20 h) incubation with Pc4 (20 nM), LCL29 (1 µM) and 4HPR (2.5 µM) 
were added immediately prior to irradiation. Cells were irradiated at room temperature with red 
light (2 mW/cm2; λmax ~ 670 nm) using a light-emitting diode array light source (EFOS, 
Mississauga, ON, Canada) at the fluence of 200 mJ/cm2. The inhibitors FB, zVAD (10 µM each) 
and ABT (0.1 µM) were added 1 h prior to treatments. 
2.4 Clonogenic assay 
In order to determine cell survival after treatments, clonogenic assay was employed to 
study the effect of treatments on colony formation ability of the cells. Modified pre-plating 
method was used as described previously in [38]. Cells were resuspended in growth medium 
with or without Pc4 and seeded (250 cells/well) in to 6-well plates (Thermo-Fisher Scientific). 
After overnight (20 h) incubation, the cells were irradiated. LCL29, 4HPR were added 
immediately prior to irradiation. The inhibitors FB, zVAD and ABT were added 1 h prior to 
treatments. After 14 days of incubation, the medium was aspirated, the plates were stained with 
crystal violet (0.1% in 20% ethanol; Sigma-Aldrich) for 30 seconds, rinsed with water and air-
dried. Colonies (≥50 cells) were counted using eCount Colony Counter (VWR International, 
Radnor, PA, USA). Plating efficiency was 36% (n = 16).  
2.5 Quantitative Confocal Microscopy  
Ceramide/dihydroceramide accumulation in mitochondria and both ER, and Bax 
associated with mitochondria and cytochrome c redistribution were visualized using 
immunofluorescence and confocal microscopy. Immunofluorescence uses fluorescent-labeled 
antibodies for detection of specific target antigens. Fluorescent-labeled antibodies bind (directly 
or indirectly) to the antigen of interest, which allows for antigen detection using confocal 
microscopy. Sample preparation procedure for confocal microscopy is outlined below. Images 
were acquired using Zeiss LSM780 confocal microscope equipped with a 100 x 1.4 NA OIL DIC 
D objective (Carl Zeiss, Thornwood, NY, USA). Confocal microscopy imaging for all 
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experiments was performed at Microscopy, Imaging and Cytometry Resources Core, School of 
Medicine, Wayne State University (Detroit, MI, USA).  
Outline of Immunofluorescence procedure for Confocal Microscopy visualization 
 
Coverslips coated with Poly-L-Lysine and dried overnight 
 
Cell setup in 6-well plates containing cover slips 
 
Treatment of the samples and incubation for indicated period of time 
 
Addition of 250 nM Mitotracker Red CMXRos to the medium containing treated cells 
(For detection of mitochondria) 
 
Incubation for 30 min  
 
Medium aspirated and coverslips washed 3 times with coldPBS 
 
Cell fixation by incubation with 4% formalin (in PBS) for 15 min 
 
Formalin aspirated and coverslips washed 3 times with coldPBS 
 
Cell permeabilization by incubation with -200C Acetone/Methanol (1:1) for 10 min 
 
Acetone/Methanol aspirated and coverslips washed 3 times with coldPBS 
 
Addition of 3% Goat Serum+ 3% FBS in PBS to wells and incubation for 1 h at 40C 
 
Serum aspirated and coverslips washed 3 times with coldPBS 
 
Incubation of coverslips with primary antibodies (diluted in 1% BSA, 0.025% Tween 20 in PBS 
solution) at room temperature for 45 min 
 
Coverslips washed 3 times with coldPBS 
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Incubation of coverslips with fluorophore-conjugated secondary antibodies (diluted in 1% bovine 
serum albumin, 0.025% Tween 20 in PBS solution) at room temperature for 45 min 
 
Coverslips washed 3 times with coldPBS 
 
Incubation of coverslips with DAPI (1 µg/ml in PBS; Life Technologies) for 10 min at room 
temperature 
 
Coverslips washed 3 times with coldPBS 
 
Coverslips mounted on to slides using Antifade kit 
 
Visualization with confocal microscopy 
 
 
Table 2.1 Primary antibodies used in quantitative confocal microscopy 
Primary antibody Target Vendor 
Anti-ceramide/dihydroceramide 
antibody 
Ceramide, Dihydroceramide Enzo Life Sciences 
Anti-KDEL antibody Endoplasmic reticulum Abcam 
Anti-Bax antibody Bax Abcam 
Anti-cyt c antibody Cytochrome c BD Pharmingen 
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Table 2.2 Secondary antibodies used in quantitative confocal microscopy 
Secondary antibody Target (Primary antibody) Vendor 
Alexa 488-conjugated Goat anti-
mouse IgM antibody 
Anti-ceramide/ dihydroceramide 
antibody 
Jackson-
Immunoresearch 
Alexa 594-conjugated Goat anti-
mouse IgG antibody 
Anti-KDEL and anti-cyt c 
antibodies 
Jackson-
Immunoresearch 
Alexa 488-conjugated Goat anti-
mouse IgG antibody 
Anti-Bax antibody Jackson-
Immunoresearch 
 
2.6 Quantification of Confocal Microscopy Images  
Ceramide/dihydroceramide fluorescence associated with the ER and the mitochondria, 
as well as Bax fluorescence associated with the mitochondria were quantified by Dr. Ursula 
Stochaj and Dr. Mohamed Kodiha, Department of Physiology, McGill University, Montreal, 
Canada. MetaXpress software version 5 5.00.20 (Molecular Devices, Sunnyvale, CA, USA) was 
used for the quantification [39]. Mitotracker CMXRos (Life Technologies) or anti-KDEL 
antibodies were used to demarcate the mitochondria or the ER. Visual inspection was used to 
verify identification of correct compartments. Multiwavelength cell scoring module was employed 
in measuring ceramide/dihydroceramide pixel intensities associated with mitochondria and ER 
and Bax pixel intensities associated with mitochondria. Prior to quantification, all the images 
were corrected for background contribution. Cytochrome c redistribution was quantified using 
visual inspection of the confocal microscopy images. Margin of cytochrome c staining greater 
than 10 µm around the nuclei was used as a criteria for scoring cells positive for cytochrome c 
redistribution. In all experiments, atleast 100 cells were assessed for each condition. 
2.7 Mass Spectrometry (MS) 
Mass spectrometry was used to determine effect of treatments on different sphingolipids. 
Ten hours after treatments, cells were collected on ice and centrifuged at 750 g for 10 min at 
40C in Allegra 6KR centrifuge (Beckman Coulter, Pasadena, CA, USA). After aspirating the 
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supernatants, cell pellets were resuspended in cold PBS. An aliquot of the sample was 
transferred to a different tube for determining protein content. Remaining sample was 
centrifuged at 325 g for 5 min at 40C in Allegra 6KR centrifuge. Supernatant was aspirated and 
cell pellet was resuspended in 1:1 mixture of methanol and ethyl acetate (EMD chemicals, 
Billercia, MA, USA). Samples were then dried under nitrogen and shipped overnight on dry ice 
to the Lipidomics shared resource facility located in Medical University of South Carolina 
(Charleston, SC, USA) for further processing. After extraction, sphingolipids were separated by 
high performance liquid chromatography and analyzed using TSQ 7000 triple quadrupole mass 
spectrometer (Thermo-Fisher Scientific) [40]. After determining protein content, pmoles of 
sphingolipids were normalized per mg protein and data were expressed as average ± SEM 
(n=3-4). 
2.8 DEVDase activity assay 
DEVDase assay was used for measuring caspase-3 activity in the cytosol as described 
previously [41]. This assay is based upon quantitative measurement of enzyme’s cleavage of a 
fluorogenic substrate N-acetyl-Asp-Glu-Val-Asp (DEVD; Enzo life sciences, Ann Arbor, MI, 
USA). Briefly, 24 h after treatments, cells were collected on ice and centrifuged at 750 g for 10 
min at 40C in Allegra 6KR centrifuge (Beckman Coulter). After aspirating the supernatants, cell 
pellets were resuspended in phosphate-buffered saline (Life Technologies). Resuspension was 
followed by centrifugation at 1650 g for 5 min at 40C in Sorvall Fresco microcentrifuge (Thermo-
Fisher Scientific). After aspirating the supernatants, cell pellets were resuspended in RIPA 
(Radioimmunoprecipitation assay) lysis buffer (VWR international) and vortexed thoroughly. 
Samples were then centrifuged at 6500 g for 10 min at 40C in Sorvall Fresco microcentrifuge 
and supernatants were collected. Protein content of the samples was determined. Volume 
containing 25 µg protein/sample was added to assay buffer and DEVD substrate, incubated for 
1 h at 370C in a water bath. Spectroflourometer (F-2500 Hitachi, New York, NY, USA; 380 nm 
excitation and 460 nm emission) was then used to measure the fluorescence of the cleaved 
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DEVD substrate. Assay buffer added to DEVD substrate without the sample was used as a 
blank. Blank value was subtracted from the treatments to get caspase-3 activity in arbitrary 
units. 
2.9 Protein determination  
Protein content was determined by a modified Bradford assay, based on the shift in 
absorption maximum (λmax) of the protein assay dye (Bio-Rad, Hercules, CA, USA) upon binding 
to proteins. Concentration of the protein in the sample was calculated by measuring the 
absorbance at 595 nm, which was proportional to amount of dye bound to the protein. Briefly, 
this procedure involves serial dilution of the samples with double distilled water to avoid 
saturation of the dye. The protein assay dye was then added to the diluted samples and 
incubated for 30 min at room temperature. Double distilled water added to the dye without any 
sample is used as a blank. After incubation, a synergy microplate reader (BioTek, Winooski, VT, 
USA) was used to measure the absorbance at 595 nm. Blank value was subtracted from the 
absorbance of treatments and used for calculating protein content. A standard curve generated 
using bovine serum albumin was employed to determine the protein content in the samples. 
2.10 Statistical analysis  
Clonogenic, mass spectrometry and DEVDase data are presented as the average ± 
SEM. Significant differences (p < 0.05) in clonogenic, mass spectrometry and DEVDase values 
was determined using student’s t-tests. One-way ANOVA was used to determine significant 
differences (p < 0.05) in confocal quantification data. Statistical analysis using one-way ANOVA 
were run by Dr. Ursula Stochaj (Department of Physiology, McGill University, Montreal, 
Canada).  
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CHAPTER 3: RESULTS AND DISCUSSION 
3.1 PDT data: 
PDT-induced cell death is inhibited by FB and zVAD and enhanced by ABT   
Our previous studies have shown that PDT-induced apoptosis requires de novo SL 
synthesis and CERS in cell lines other than SCC17B cells [10-12]. However, it is not known 
whether the PDT-induced cell killing requires CERS. Bcl2 protects against PDT-induced cell 
killing in apoptosis-competent cells (e.g. human breast cancer MCF-7 cells overexpressing 
human pro-caspase 3) [42]. However, it has yet to be determined whether in SCC17B cells, 
apoptosis is essential for PDT-induced killing.  It is also not known whether inhibition of Bcl2 
sensitizes these cells to PDT. To define the requirement for CERS, caspases, and Bcl2 in PDT-
induced cell killing, different pharmacological inhibitors were employed: the CERS inhibitor FB, 
the pan-caspase inhibitor zVAD, and the Bcl2 inhibitor ABT. All inhibitors FB, zVAD and ABT 
were used at non-toxic doses. PDT was used at LD20 (20 nM Pc4+ 200 mJ/cm2), as 
determined in dose-response studies (not shown). As shown in figure 3.1, FB and zVAD- 
inhibited cell killing after PDT by 68 and 56%, respectively. ABT enhanced PDT-induced cell 
killing by 61% (Fig 3.1). Together, the data indicate that PDT-induced cell killing depends on 
CERS, caspase activation, and Bcl2. 
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Figure 3.1 PDT-induced cell killing is sensitive to FB, zVAD and ABT. FB, zVAD (10 µM each) 
and ABT (0.1 µM) were added 1 h prior to PDT (20 nM Pc4+200 mJ/cm
2
). Colonies were 
stained with crystal violet (0.1%) and counted 14 days after treatments. The data are shown as 
the average ± SEM (n = 6-18).  Significant differences are shown between: †, treatment and 
untreated control; #, (treatment + inhibitor) and treatment. Untreated controls had 0% loss of 
clonogenicity (Taken from Photochem. Photobiol. 13, 1621-27, 2014). 
 
PDT-induced ceramide/dihydroceramide accumulation in the ER and mitochondria is 
inhibited by FB 
The subcellular localization of ceramide correlates with the specificity of its biological 
effects. CERS-dependent ceramide accumulation has been associated with ER stress and 
apoptosis [43]. On the other hand, FB-sensitive mitochondrial ceramide accumulation has been 
linked to radiation-induced apoptosis [44]. We have previously shown that PDT-induced 
ceramide accumulation involves the de novo SL biosynthesis and CERS [10-12], which implies 
generation of ceramide in the ER. However, experimental evidence for PDT-induced ceramide 
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accumulation in the ER is missing. Also, evidence that PDT induces mitochondrial ceramide 
accumulation is lacking.  
 
Figure 3.2 PDT-induced ceramide/dihydro-
ceramide accumulation in the ER is inhibited by 
FB. Where indicated, cells were treated with FB 
(10 µM) 1 h prior to PDT (20 nM Pc4+200 
mJ/cm2; LD20), incubated for indicated periods 
of time, and immunostained with anti-
ceramide/dihydroceramide and anti-KDEL 
antibodies. Nuclei were visualized with DAPI. All 
images were acquired using identical settings (B) 
Ceramide/dihydroceramide fluorescence in the 
ER (pixel intensity/ER area) was quantified using 
MetaXpress software and plotted as a bar graph. 
At least 323 regions were measured for each 
data point. Significant differences are shown 
between: †, treatment and untreated control; #, 
(treatment + FB) and treatment. Con, control; 
Cer, Ceramide; DHCer, Dihydroceramide. 
(Taken from Photochem. Photobiol. 13, 1621-27, 
2014)  
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Figure 3.3 PDT-induced ceramide/dihydro-
ceramide accumulation in the mitochondria is 
inhibited by FB. Where indicated, cells were 
treated with FB (10 µM) 1 h prior to PDT (20 nM 
Pc4+200 mJ/cm2; LD20), incubated for 
indicated periods of time and immunostained 
with anti-ceramide/dihydroceramide antibodies. 
Prior to immunostaining with anti-
ceramide/dihydroceramide antibodies, cells 
were incubated with Mitotracker Red CMXRos. 
(B) MetaXpress software was used to quantify 
ceramide/dihydroceramide fluorescence in the 
mitochondria (pixel intensity/mitochondrial 
area). Quantification values were plotted as a 
bar graph. A minimum of 292 regions were 
measured for each data point. Significant 
differences are shown between: †, treatment 
and untreated control; #, (treatment + FB) and 
treatment. Con, control; Mito, mitochondria. 
Con, control Cer, Ceramide; DHCer, 
Dihydroceramide (Taken from Photochem. 
Photobiol. 13, 1621-27, 2014). 
 
Here, we used for the first time quantitative confocal microscopy to measure 
ceramide/dihydroceramide in mitochondria and the ER. To this end, ceramide/dihydroceramide 
was detected by immunostaining; Mitotracker and KDEL served as markers of mitochondria and 
the ER, respectively. As depicted in Figures 3.2 and 3.3, we determined the accumulation of 
ceramide/dihydroceramide in the ER and mitochondria at 2, 10 and 24 h post-PDT. 
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Ceramide/dihydroceramide accumulation at both subcellular sites increased post-PDT, as 
quantification data revealed (Fig. 3.2.B and 3.3.B). Next we used FB to test whether PDT-
induced ceramide/dihydroceramide accumulation is CERS-dependent.  FB reduced 
ceramide/dihydroceramide accumulation in the ER and mitochondria post-PDT at all-time points 
[Fig. 3.2 and 3.3]. This was also confirmed by the quantification analysis (Fig. 3.2.B and 3.3.B). 
Together these results reveal that PDT induces ceramide/dihydroceramide accumulation in the 
ER and mitochondria. The data suggest that PDT-induced ceramide/dihydroceramide 
accumulation at ER and mitochondria is CERS-dependent. 
MS reveals increases in ceramides post-PDT    
To validate confocal microscopy findings, we used MS to identify ceramide species 
accumulated in response to PDT. The levels of most of the individual ceramides were 
significantly increased after PDT [Table 3.2]. PDT also increased the levels of C16-
dihydroceramide, a precursor of ceramide in de novo SL biosynthesis. Overall, our data 
demonstrate increases in the levels of ceramides and C16-dihydroceramide post-PDT. They 
also suggest the involvement of the de novo SL biosynthesis. 
PDT-induced Bax translocation to mitochondria and cyt c redistribution are inhibited by 
FB 
The translocation of the pro-apoptotic protein Bax from the cytosol to mitochondria and 
the redistribution of cyt c from the mitochondria to the cytosol are hallmarks of the mitochondrial 
pathway of apoptosis and have been demonstrated in response to PDT [9, 15, 17, 45]. 
However, it is not known whether PDT induces Bax associated with mitochondria and cyt c 
redistribution in SCC17B cells. It is also not clear whether these processes are CERS-
dependent. Using quantitative confocal microscopy, we determined whether Bax associated 
with mitochondria and cyt c redistribution are induced by PDT and sensitive to FB.  As shown in 
Figure 3.4, Bax associated with mitochondria was induced at 2 and 10 h post-PDT. In the 
presence of FB, this process was inhibited.  Cyt c redistribution was observed at 10 h post-PDT 
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[Fig. 3.5] but not earlier (not shown). Co-treatment of cells with FB and PDT led to inhibition of 
cyt c redistribution. Together, these results indicate that PDT induces Bax associated with 
mitochondria and cyt c redistribution in SCC17B cells.  Moreover, both processes are CERS-
dependent.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 PDT-induced Bax associated with mitochondria is inhibited by FB. FB (10 µM) was 
added 1 h prior to PDT (20 nM Pc4+200 mJ/cm2; LD20). Cells were incubated for indicated 
periods of time and then immunostained with anti-Bax antibodies. Incubation with Mitotracker 
Red CMXRos was carried out prior to immunostaining with anti-Bax antibodies. Images were 
acquired by confocal microscopy using identical settings. (B) Bax fluorescence associated with 
mitochondria was quantified using MetaXpress software.  The data were calculated as Bax-pixel 
intensities/mitochondrial area. A minimum of 277 regions were measured for each data point. 
Results are shown as the average ±SEM. Significant differences are shown between: †, 
treatment and untreated control; #, (treatment + FB) and treatment. Con, untreated control 
(Taken from Photochem. Photobiol. 13, 1621-27, 2014)  
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Figure 3.5 PDT-induced cytochrome c redistribution is inhibited by FB. FB (10 µM) was added 1 
h prior to PDT (20 nM Pc4+200 mJ/cm2; LD20). Cells were incubated for indicated periods of 
time and then immunostained with anti-cyt c antibodies. Images were acquired by confocal 
microscopy using identical settings. (B) Percentages of cells with cyt c redistribution were 
calculated by scoring 100 cells for every sample and were plotted as bar graph. Each data point 
represents 3-4 samples and the data are shown as the average ± SEM. Significant differences 
are shown between: †, treatment and untreated control; #, (treatment + FB) and treatment. Con, 
untreated control (Taken from Photochem. Photobiol. 13, 1621-27, 2014). 
 
FB inhibits caspase-3 activation after PDT 
DEVDase assay was used to test the activation of caspase-3 after PDT. As shown in 
figure 3.10, caspase-3 was activated at 24 h post-PDT. Co-treatment of cells with FB and PDT 
led to inhibition of caspase-3 activation.  
Conclusion 
The present studies demonstrate that inhibition of CERS and caspases protect cells 
from PDT-induced killing, indicating that PDT induces apoptotic cell killing in SCC17B cells via 
CERS.  In addition, inhibition of Bcl2 enhances PDT-induced cell killing in these cells, which 
further supports the idea that apoptosis is involved. PDT-induced accumulation of 
ceramide/dihydroceramide in the ER and mitochondria is inhibited by FB. PDT-induced Bax 
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associated with mitochondria, and cytochrome c redistribution, are sensitive to FB. These 
findings highlight the functional significance of mitochondrial apoptosis and CERS in cell killing 
in response to PDT. In summary, these results suggest that CERS-dependent 
ceramide/dihydroceramide accumulation is required for apoptotic cell death after PDT. 
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3.2 PDT+4HPR data: 
Enhanced cell killing after PDT+4HPR is FB-, zVAD- and ABT-sensitive 
Clonogenic assay was used to test whether combining PDT with 4HPR sensitizes 
SCC17B cells to PDT.  As shown in Table 3.1, when PDT and 4HPR were used at LD20 each, 
i.e. the dose reducing survival by 20%, 63% of PDT+4HPR-treated cells were unable to form 
colonies.  To determine whether apoptosis and ceramide synthase are necessary for enhanced 
cell killing after PDT+4HPR, pancaspase inhibitor zVAD, the Bcl2 inhibitor ABT, and the 
ceramide synthase inhibitor FB were used. All inhibitors were non-toxic (LD < 5).  FB and zVAD 
rendered the cells resistant not only to PDT and 4HPR alone, but also to PDT+4HPR.  In 
contrast, ABT sensitized SCC17B cells to PDT±4HPR. This suggest that PDT+4HPR-induced 
enhanced cell killing of SCC17B cells depends on ceramide synthase, caspase activation and 
inhibition of Bcl2.   
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Table 3.1 PDT+4HPR-induced augmented cell killing is FB-, zVAD- and ABT-sensitive.   
Treatment                 % Survival 
4HPR 80 ± 0.6a 
4HPR+FB      91 ± 0.9a,b 
4HPR+zVAD      95 ± 1.0b 
4HPR+ABT     73 ± 0.7a,b 
PDT 79 ± 0.6a 
PDT+FB    93 ± 0.7b 
PDT+zVAD    91 ± 1.3a,b 
PDT+ABT  67 ± 2.2a,b 
PDT+4HPR  37 ± 0.7a,c 
PDT+4HPR+FB 73 ± 1.7a,b 
PDT+4HPR+zVAD 91 ± 1.6b 
PDT+4HPR+ABT 32 ± 0.9a,b 
FB, zVAD (10 µM each) and ABT (0.1 µM) were added 1 h prior to PDT (20 nM Pc4+200 
mJ/cm2), 4HPR (2.5 µM) or the combination. Colonies were stained with crystal violet (0.1%) 
and counted 14 days after treatments. The data are shown as the average ± SEM (n = 3-18 
samples).  Significant differences are shown between: a, treatment and untreated control; b, 
(treatment + inhibitor) and treatment; c, combination and individual treatments (Taken from Int. 
J. Oncol. 46, 2003-10, 2015). 
 
PDT+4HPR enhances ceramide/dihydroceramide accumulation in the ER. FB inhibits 
ceramide/dihydroceramide accumulation in the ER and mitochondria after PDT±4HPR 
Because the de novo SL biosynthesis pathway is localized to the ER, we tested the 
effect of combining PDT with 4HPR on dihydroceramide/ceramide accumulation in the ER.  
Using an antibody that recognizes dihydroceramide and ceramide [46] and the ER marker anti-
KDEL for quantitative confocal microscopy, we found that PDT+4HPR enhanced 
dihydroceramide/ceramide accumulation in the ER (Fig. 3.6). This effect was inhibited by FB. It 
is unknown what impact on mitochondrial dihydroceramide/ceramide accumulation combining 
PDT with 4HPR might have. Using the same anti-dihydroceramide/ceramide antibody and the 
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mitochondrial marker Mitotracker for quantitative confocal microscopy, we found that PDT and 
4HPR alone did induce mitochondrial dihydroceramide/ceramide accumulation (Fig. 3.6).  
However, the effect was not enhanced after PDT+4HPR.  FB inhibited mitochondrial ceramide 
accumulation after all treatments. 
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Figure 3.6 PDT+4HPR enhanced ceramide/dihydroceramide accumulation in the ER is 
inhibited by FB. FB inhibits ceramide/dihydroceramide accumulation in mitochondria after 
PDT±4HPR. Cells were treated with FB (10 µM) 1 h prior to PDT (20 nM Pc4+200 mJ/cm2; 
LD20), 4HPR (2.5 µM; LD20), or the combination, incubated for 10 h, immunostained with anti-
ceramide/dihydroceramide and, anti-KDEL antibodies (A, C). (B, D) Incubation with Mitotracker 
Red CMXRos was carried out prior to immunostaining with anti-ceramide antibodies. Nuclei 
were visualized with DAPI. All images were acquired by confocal microscopy with identical 
settings. MetaXpress software was used to quantify ceramide/dihydroceramide fluorescence 
located in the ER (B) and mitochondria (D). (B and D) Data are shown as the average ± SEM. 
The graphs depict ceramide/dihydroceramide fluorescence/ER area (B), or 
ceramide/dihydroceramide fluorescence/mitochondrial area (D). Results were normalized to the 
untreated control. Significant differences are shown between: †, treatment and untreated 
control; #, (treatment + FB) and treatment; *, combination and individual treatments. Con, 
control; Cer, Ceramide; DHCer, Dihydroceramide (Taken from Int. J. Oncol. 46, 2003-10, 2015). 
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PDT+4HPR enhances C16-dihydroceramide, not ceramide, accumulation 
Both PDT and 4HPR regulate the de novo SL biosynthesis pathway [10, 41, 47, 48]. The 
question is what the effects of combining PDT with 4HPR on the cellular SL profile are.  We 
used MS to address the question. As depicted in Figure 3.7.A, in contrast to 4HPR, PDT 
increased total ceramide accumulation. Combining PDT with 4HPR attenuated PDT-induced 
increase in total ceramide levels. The accumulation of individual ceramides, by and large, 
followed the same pattern (Table 3.2). 4HPR did not significantly raise the levels of any 
individual ceramide. In contrast, 4HPR increased accumulation of C16-dihydroceramide, a de 
novo SL biosynthesis pathway metabolite by 445% above basal levels (Fig. 3.7.B). PDT also 
increased the levels of C16-dihydroceramide by 138% beyond resting levels. Combining PDT 
with 4HPR enhanced accumulation of C16-dihydroceramide by 632%. These results show that 
PDT+4HPR led to increase in C16-dihydroceramide levels rather than individual and total 
ceramide levels.  
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Figure 3.7 Effect of PDT+4HPR on total ceramide levels (A). PDT+4HPR enhances C16-
dihydroceramide accumulation (B). Cells were treated with PDT (20 nM Pc4 + 200 mJ/cm2; 
LD20), 4HPR (2.5 µM; LD20) or the combination, incubated for 10 h, collected and processed 
for MS. The levels of sphingolipids were calculated as pmoles/mg protein and are shown as the 
average ± SEM (n=3-4). Significant differences are shown between: †, treatment and untreated 
control; *, combination and individual treatments. Con, untreated control (Taken from Int. J. 
Oncol. 46, 2003-10, 2015). 
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Table 3.2 Effect of PDT ± 4HPR on individual ceramides in SCC17B cells. 
Ceramide         Con         4HPR         PDT PDT+4HPR 
C14-ceramide    16.1 ± 0.9     16.7 ± 1.8    29.4 ± 1.7
a    22.6 ± 0.8a,d 
C16-ceramide  91.0 ± 11.9    51.7 ± 6.4
a  129.6 ± 8.5a   93.5 ± 3.6d 
C18-ceramide    17.8 ± 2.1     21.5 ± 3.0    61.6 ± 4.2
a    48.3 ± 0.8a,d 
C18:1-ceramide      7.6 ± 0.3     10.8 ± 1.1    25.5 ± 2.6
a       22.4 ± 0.8a,b 
C20-ceramide      5.2 ± 0.7       9.1 ± 0.5    21.4 ± 1.8
a     17.6 ± 1.2a,b 
C20:1-ceramide      1.5 ± 0.2       2.3 ± 0.2      5.3 ± 0.6
a       3.9 ± 0.3a 
C22-ceramide    51.6 ± 2.7     37.5 ± 3.2 132.7 ± 10.6
a    100.3 ± 3.0a,d 
C22:1-ceramide    18.7 ± 1.7     16.1 ± 1.9   49.6 ± 4.5
a     34.6 ± 1.5a,d 
C24-ceramide  161.9 ± 9.1     97.7 ± 5.1 252.6 ± 22.4
a  175.2 ± 8.9d 
C24:1-ceramide  199.3 ± 9.4  110.0 ± 8.6
a 305.4 ± 28.6a  196.7 ± 9.0d 
C26-ceramide 15.8 ± 3.6 10.6 ± 0.8 13.9 ± 1.3 11.0 ± 1.0 
C26:1-ceramide 33.4 ± 3.2 20.1 ± 1.8a 33.5 ± 2.3 23.0 ± 2.3
a,c 
SCC17B cells were treated with PDT (20 nM Pc4+200 mJ/cm2), 4HPR (2.5 µM) or the 
combination, incubated for 10 h, collected, and processed for MS.  Ceramide levels were 
calculated as pmoles/mg protein and are shown as the average ± SEM (n=3-4). Significant 
differences are shown between: a, treatment and untreated control; b, combination and 4HPR; 
c, combination and PDT; d, combination and both individual treatments. Con, untreated control 
(Taken from Int. J. Oncol. 46, 2003-10, 2015). 
 
PDT+4HPR-enhanced Bax associated with mitochondria and cyt c redistribution is 
inhibited by FB.   
The mitochondrial apoptosis pathway, including Bax translocation to mitochondria and 
cyt c redistribution, is induced by PDT and 4HPR [16, 18, 19]. The question is whether the 
mitochondrial apoptosis pathway is affected by combining PDT with 4HPR, and whether the 
process is ceramide synthase-dependent. Using quantitative confocal microscopy, we found 
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that Bax associated with mitochondria and cyt c redistribution were induced after PDT and 
4HPR (Figs. 3.8 and 3.9). PDT+4HPR enhanced Bax associated with mitochondria and cyt c 
redistribution, and FB inhibited both processes.  
 
Figure 3.8 PDT+4HPR-induced enhanced Bax 
associated with mitochondria is inhibited by FB. 
FB (10 µM) was added 1 h prior to PDT (20 nM 
Pc4+200 mJ/cm2; LD20), 4HPR (2.5 µM; LD20) 
or the combination. Incubation time was 10 h 
post-treatments. After treatments, cells were 
immunostained with anti-Bax antibodies. 
Incubation with Mitotracker Red CMXRos was 
carried out prior to immunostaining with anti-Bax 
antibodies. Nuclei were visualized with DAPI. 
Images were acquired with confocal microscopy 
using identical settings. (B) Bax fluorescence 
located in the mitochondria was quantified with 
MetaXpress software. The graph shows Bax 
fluorescence/mitochondria area. Each data point 
represents a minimum of 488 regions. The data 
were normalized to the untreated control. 
Results are shown as the average ± SEM. 
Significant differences are shown between: †, 
treatment and untreated control; #, (treatment + 
FB) and treatment; *, combination and individual 
treatments.  Con, untreated control (Taken from 
Int. J. Oncol. 46, 2003-10, 2015). 
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Figure 3.9 PDT+4HPR-induced enhanced cytochrome c redistribution is inhibited by FB. FB (10 
µM) was added 1 h prior to PDT (20 nM Pc4+200 mJ/cm2; LD20), 4HPR (2.5 µM; LD20) or the 
combination. Incubation time was 10 h post-treatments. After treatments, cells were 
immunostained with anti-cyt c antibodies. Nuclei were visualized with DAPI. Images were 
acquired with confocal microscopy using identical settings. Arrow (=>) indicates cyt c 
redistribution. (B) To calculate percentages of cells with redistributed cyt c, at least 100 cells 
were scored for every samples. Each bar indicates an average ± SEM from 3-4 samples. 
Significant differences are shown between: †, treatment and untreated control; #, (treatment + 
FB) and treatment; *, combination and individual treatments.  Con, untreated control (Taken 
from Int. J. Oncol. 46, 2003-10, 2015).  
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Enhanced caspase-3 activation induced by PDT+4HPR is inhibited by FB 
The effect of combining PDT with 4HPR on caspase-3 activation was determined using 
DEVDase assay. PDT+4HPR led to enhanced caspase-3 activation at 24 h post-treatments. FB 
led to inhibition of caspase-3 activation after all the treatments (Figure 3.10). Taken together, 
data indicates that CERS is involved in enhanced caspase-3 activation after PDT+4HPR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 PDT+4HPR enhanced FB-sensitive caspase-3 activation. FB (10 µM) was added 
1 h prior to PDT (250 nM Pc4 + 200 mJ/cm
2
), 4HPR (5 µM) or the combination. Twenty-four 
h after treatments, cells were collected and processed for DEVDase assay. The data are shown 
as the average ± SEM (n=3-9 samples). Significant differences are shown between: †, 
treatment and untreated control; #, (treatment + FB) and treatment; *, combination and 
individual treatments. Con, control.  
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Conclusion: 
The data suggests that enhanced killing of SCC17B cells after PDT+4HPR depends on 
ceramide synthase, caspase activation and Bcl2. Combining PDT with 4HPR led to enhanced 
ER ceramide/dihydroceramide accumulation, Bax associated with mitochondria and cytochrome 
c redistribution, which were inhibited by FB. PDT+4HPR-induced enhanced C16-
dihydroceramide levels but led to attenuation of PDT-induced increase in total and individual 
ceramide levels. Taken together, these results show that combining PDT with 4HPR enhances 
cell killing via the de novo SL biosynthesis and mitochondrial apoptotic pathway.  
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3.3 PDT+LCL29 data: 
Enhanced cell killing after PDT+LCL29 is FB- and zVAD-sensitive 
The clonogenic assay was employed to test whether combining PDT with LCL29 
improves PDT efficacy.  Each treatment was used at LD20, as determined in dose-response 
studies (not shown).  As depicted in Figure 3.11, combining PDT with LCL29 led to a significant 
increase in cell killing. To determine whether apoptosis and ceramide synthase are necessary 
for enhanced cell killing after PDT+LCL29, we used zVAD and FB. The inhibitors alone were 
non-toxic (LD < 5). As shown in Figure 3.11, FB and zVAD rescued cells from death not only 
after PDT and LCL29 alone, but also after PDT+LCL29. ABT did not have an effect on 
PDT+LCL29-induced enhanced cell killing. The data suggest that enhanced cell killing after 
PDT+LCL29 is mediated by ceramide synthase and caspases.  
 
Figure 3.11 Combining PDT with LCL29 enhances loss of clonogenicity in SCC17B cells. The 
clonogenic potential of PDT±LCL29-treated cells is rescued in the presence of FB and zVAD. 
FB, zVAD (10 µM each) and ABT (0.1 µM) were added 1 h prior to PDT (20 nM Pc4+200 
mJ/cm
2
), LCL29 (1 µM) or the combination. Colonies were stained with crystal violet (0.1%) and 
counted 14 days after treatments. The data are shown as the average ± SEM (n = 3-18 
samples).  Significant differences are shown between: †, treatment and untreated control; #, 
(treatment + inhibitor) and treatment; *, combination and individual treatments.   
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PDT+LCL29 enhances FB-sensitive ceramide/dihydroceramide accumulation in the 
mitochondria 
The biological effects of sphingolipids depend on subcellular site of their generation [49].  
Although it has been shown that LCL29 accumulates in mitochondria, it is not known whether 
mitochondrial ceramide accumulation is induced after LCL29 alone or in combination with PDT. 
Using the anti-ceramide/dihydroceramide antibody and the mitochondrial marker Mitotracker for 
quantitative confocal microscopy, we found that PDT and LCL29 alone did induce mitochondrial 
ceramide/dihydroceramide accumulation (Fig. 3.12).  Notably, the effect was enhanced after 
PDT+LCL29.  FB inhibited mitochondrial ceramide/dihydroceramide accumulation after PDT 
alone or in combination, not after LCL29. Overall, the results suggest ceramide synthase-
dependent enhanced mitochondrial ceramide/dihydroceramide accumulation after PDT+LCL29. 
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Figure 3.12 PDT+LCL29 enhanced FB-sensitive ceramide/dihydroceramide accumulation in the 
mitochondria. Cells were treated with FB (10 µM) 1 h prior to PDT (20 nM Pc4+200 mJ/cm2; 
LD20), LCL29 (1 µM; LD20) or the combination, and incubated for 10 h. Incubation with 
Mitotracker Red CMXRos was carried out prior to immunostaining with anti-
ceramide/dihydroceramide antibodies. Nuclei were visualized with DAPI. All images were 
acquired by confocal microscopy with identical settings. MetaXpress software was used to 
quantify ceramide/dihydroceramide fluorescence located in the mitochondria. Data are shown 
as the average ± SEM. The graph depicts ceramide/dihydroceramide fluorescence (pixel 
intensity)/mitochondrial area. Results were normalized to the untreated control. A minimum of 
195 regions were measured for each data point. Significant differences are shown between: †, 
treatment and untreated control; #, (treatment + FB) and treatment. Con, control Cer, Ceramide; 
DHCer, Dihydroceramide (Taken from J. Photochem. Photobiol., B 143, 163-8, 2015). 
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PDT+LCL29 effect on total ceramides 
Mass spectrometry data revealed that cellular levels of total ceramides were increased 
after PDT (Fig. 3.13).  LCL29 did not induce any significant cellular ceramide accumulation.  
Combining PDT with LCL29 did not raise cellular ceramide levels beyond PDT-induced 
increases in ceramide. The apparent discrepancy between mass spectrometry and confocal 
microscopy findings for LCL29 alone and the combination argues for measuring ceramide 
accumulation not only in whole cells but also at a subcellular level.  This is important because 
the subcellular sites of ceramide accumulation affect the specificity of biological effects of this 
hydrophobic sphingolipid [49].   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Effect of PDT±LCL29 on total ceramide levels. Cells were treated with PDT (20 nM 
Pc4 + 200 mJ/cm2; LD20), LCL29 (1 µM; LD20) or the combination, incubated for 10 h, 
collected, and processed for MS. The levels of sphingolipids were calculated as pmoles/mg 
protein and are shown as the average ± SEM (n=3-4). Significant differences are shown 
between: †, treatment and untreated control; a, (PDT+LCL29) and LCL29. Con, untreated 
control (Taken from J. Photochem. Photobiol., B 143, 163-8, 2015).  
35 
 
PDT+LCL29-induced enhanced cyt c redistribution is inhibited by FB 
The mitochondrial apoptosis pathway, including cyt c redistribution, is induced by PDT 
and LCL29 [22, 45]. The question is whether cyt c redistribution is regulated by combining PDT 
with LCL29 and whether the process is ceramide synthase-dependent. Using quantitative 
confocal microscopy, we found that cells treated with PDT or PDT+LCL29 showed an enhanced 
redistribution of cyt c staining (Fig. 3.14). In the presence of FB, cyt c redistribution was 
prevented after PDT alone or in combination, not after LCL29 itself.  The data indicate ceramide 
synthase-dependent cyt c redistribution post-PDT with or without LCL29.   
 
Figure 3.14 PDT+LCL29 enhances FB-sensitive 
cytochrome c redistribution. FB (10 µM) was 
added 1 h prior to PDT (20 nM Pc4+200 mJ/cm2; 
LD20), LCL29 (1 µM; LD20) or the combination. 
Incubation time was 10 h post-treatments. After 
treatments, cells were immunostained with anti-
cyt c antibodies. Images were acquired by 
confocal microscopy using identical settings. 
Arrow (=>) indicates cyt c redistribution. (B) To 
calculate percentages of cells with redistributed 
cyt c, at least 100 cells were scored for every 
sample. Each bar indicates an average ± SEM 
from 3-4 samples. Significant differences are 
shown between: †, treatment and untreated 
control; #, (treatment + FB) and treatment; *, 
combination and individual treatments.  Con, 
untreated control (Taken from J. Photochem. 
Photobiol., B 143, 163-8, 2015). 
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FB inhibits enhanced caspase-3 activation induced by PDT+LCL29  
The effect of treatments on caspase-3 activation was tested using DEVDase assay. As 
shown in figure 3.15, enhanced caspase-3 activation was observed with PDT+LCL29. Caspase-
3 activation after PDT and PDT+LCL29 were inhibited by FB. This shows that CERS is involved 
in enhanced caspase-3 activation after PDT+LCL29. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 PDT+LCL29 enhanced FB-sensitive caspase-3 activation. FB (10 µM) was added 
1 h prior to PDT (250 nM Pc4 + 200 mJ/cm
2
), LCL29 (5 µM) or the combination. Twenty-four 
h after treatments, cells were collected and processed for DEVDase assay. The data are shown 
as the average ± SEM (n=3-12 samples).  Significant differences are shown between: †, 
treatment and untreated control; #, (treatment + FB) and treatment; *, combination and 
individual treatments. Con, control (Taken from J. Photochem. Photobiol., B 143, 163-8, 2015). 
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Conclusion: 
 Combining PDT with LCL29 resulted in enhanced cell killing via ceramide synthase and 
caspases. Enhanced, FB-sensitive mitochondrial ceramide/dihydroceramide accumulation 
correlates with enhanced mitochondrial apoptosis and cell killing after combining PDT and 
LCL29. FB sensitivity of the mitochondrial ceramide/dihydroceramide accumulation, cyt c 
redistribution and caspase-3 were shown for PDT alone or in combination, but not for LCL29. 
The data further support the role for ceramide synthase-dependent mitochondrial 
ceramide/dihydroceramide accumulation and apoptosis in advancing cytotoxicity of PDT by 
combination with LCL29.  
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CHAPTER 4: SUMMARY AND FUTURE DIRECTIONS 
SUMMARY 
In summary, the data indicate that PDT-induced cell killing was mediated by ceramide 
synthase-dependent ceramide/dihydroceramide accumulation and mitochondrial apoptosis. 
These findings highlight the role of modulating de novo sphingolipid biosynthesis in cell killing 
after PDT. The data also suggest that drugs like LCL29 and 4HPR increase the sensitivity of 
SCC17B human head and neck squamous cell carcinoma cells to PDT via de novo sphingolipid 
biosynthesis and mitochondrial apoptotic pathway. Figure 4.1 below summarizes the proposed 
model of cell killing based on the findings of this study. 
 
Figure 4.1 Model of cell killing  
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FUTURE DIRECTIONS 
This study has shown that de novo generated ceramide/dihydroceramide accumulation 
and mitochondrial apoptosis play a key role in cell killing after PDT, PDT+4HPR and 
PDT+LCL29. These results highlight the role of modulating ceramide/dihydroceramide 
accumulation to improve cell killing after PDT and combinations. But, the mechanism through 
which ceramide/dihydroceramide accumulation is involved in mitochondrial apoptosis and cell 
killing is still unknown. Studies have shown that radiation induces formation of ceramide-rich 
macrodomains in outer mitochondrial membrane. Formation of mitochondrial ceramide-rich 
macrodomains facilitated cytochrome c release leading to apoptotic cell death [44]. Future 
directions involve testing the presence of mitochondrial ceramide-rich macrodomains after PDT 
and how these are involved in cell killing. This opens a new frontier for anti-cancer treatments 
that modulate the formation of these mitochondrial ceramide-rich macrodomains to induce 
apoptosis.  
Apart from this, pharmacological inhibitors are not always the best tools to test the role 
of different targets in cell killing. Further studies also include using molecular biology tools like 
siRNA to knockdown different targets like ceramide synthase, Bcl2 and caspases to validate 
their role in cell killing after Pc4PDT and combinations. From the study, Bcl2 has been shown to 
be involved in cell killing after PDT.   
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APPENDIX 
Portions of the text and associated figures in chapters 2 and 3 were taken from prior 
publications [50-52] (Photochem. Photobiol. 13, 1621-27, 2014; J. Photochem. Photobiol., B 
143, 163-8, 2015; Int. J. Oncol. 46, 2003-10, 2015).  
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ABSTRACT 
COMBINATION OF PHOTODYNAMIC THERAPY WITH FENRETINIDE AND  
C6-PYRIDINIUM CERAMIDE ENHANCES KILLING OF SCC17B HUMAN HEAD  
AND NECK SQUAMOUS CELL CARCINOMA CELLS VIA THE DE NOVO  
SPHINGOLIPID BIOSYNTHESIS AND MITOCHONDRIAL APOPTOSIS 
by 
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Major:       Pharmaceutical Sciences 
Degree:    Master of Science 
The ceramide generated via the de novo sphingolipid biosynthesis has been shown to 
regulate apoptosis and cell death. The de novo sphingolipid biosynthesis includes ceramide 
synthase (CERS)-dependent acylation of dihydrosphingosine, giving rise to dihydroceramide, 
which is then converted to ceramide by a desaturase-dependent reaction. The mitochondrial 
pathway of apoptosis, characterized by induction of Bax associated with mitochondria and 
cytochrome c release/redistribution. Bcl2, an anti-apoptotic protein blocks apoptosis by inhibiting 
Bax. Elucidating the role of de novo sphingolipid biosynthesis and mitochondrial apoptosis in 
PDT, PDT+4HPR and PDT+LCL29 could help in improving the effectiveness on these anti-
cancer treatments. The objective of this study was to determine the involvement of de novo 
sphingolipid biosynthesis and mitochondrial apoptosis in PDT-induced cell killing and testing 
whether combining LCL29 and 4HPR with PDT enhances cell killing via de novo sphingolipid 
biosynthesis and mitochondrial apoptosis. Silicon phthalocyanine Pc4 was used as a 
photosensitizer for PDT and SCC17B human head and neck squamous cell carcinoma cells 
were used in this study.  
Results indicate that ceramide synthase, caspases and Bcl2 were involved in PDT-
induced cell killing. PDT-induced ER and mitochondrial ceramide/dihydroceramide accumulation 
49 
 
was inhibited by fumonisin B1 (FB) indicating involvement of ceramide synthase. PDT led to 
increase in majority of individual ceramides and C16-dihydroceramide. FB inhibited 
mitochondrial apoptotic events like PDT-induced Bax associated with mitochondria, cytochrome 
c redistribution and caspase-3 activation. The data suggests that PDT-induced cell killing is 
mediated by ceramide synthase-dependent ceramide/dihydroceramide accumulation and 
mitochondrial apoptosis. Combining PDT with 4HPR led to enhanced cell killing via ceramide 
synthase, caspases and Bcl2. PDT+4HPR enhanced ceramide synthase-dependent ER 
ceramide/dihydroceramide accumulation. Combining PDT with 4HPR enhances C16-
dihydroceramide levels but leads to attenuation of total and individual ceramide levels compared 
to PDT. PDT+4HPR-induced enhanced FB-sensitive Bax associated with mitochondria and 
cytochrome c redistribution. These data indicate that combining PDT with 4HPR enhanced cell 
killing via de novo sphingolipid biosynthesis and mitochondrial apoptosis. Combining PDT with 
LCL29 resulted in enhanced cell killing via ceramide synthase and caspases. PDT+LCL29-
induced enhanced ceramide/dihydroceramide accumulation in the mitochondria was inhibited by 
FB. PDT+LCL29 enhanced cytochrome c redistribution and caspase-3 activation were inhibited 
by FB. Taken together, this study has shown that de novo sphingolipid biosynthesis and 
mitochondrial apoptosis play a key role in killing of SCC17B human head and neck squamous 
cell carcinoma cells after PDT, PDT+4HPR and PDT+LCL29.  
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